203 related articles for article (PubMed ID: 32244296)
1. Effect of Substrate Reduction Therapy in Comparison to Enzyme Replacement Therapy on Immune Aspects and Bone Involvement in Gaucher Disease.
Limgala RP; Goker-Alpan O
Biomolecules; 2020 Mar; 10(4):. PubMed ID: 32244296
[TBL] [Abstract][Full Text] [Related]
2. Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat.
Mikosch P; Reed M; Baker R; Holloway B; Berger L; Mehta AB; Hughes DA
Calcif Tissue Int; 2008 Jul; 83(1):43-54. PubMed ID: 18553043
[TBL] [Abstract][Full Text] [Related]
3. Time of Initiating Enzyme Replacement Therapy Affects Immune Abnormalities and Disease Severity in Patients with Gaucher Disease.
Limgala RP; Ioanou C; Plassmeyer M; Ryherd M; Kozhaya L; Austin L; Abidoglu C; Unutmaz D; Alpan O; Goker-Alpan O
PLoS One; 2016; 11(12):e0168135. PubMed ID: 27942037
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy reverses B lymphocyte and dendritic cell dysregulations in patients with Gaucher Disease.
Limgala RP; Jani C; Ioanou C; Alpan O; Goker-Alpan O
Blood Cells Mol Dis; 2018 Feb; 68():81-85. PubMed ID: 27839980
[TBL] [Abstract][Full Text] [Related]
5. Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapy.
Marshall J; McEachern KA; Chuang WL; Hutto E; Siegel CS; Shayman JA; Grabowski GA; Scheule RK; Copeland DP; Cheng SH
J Inherit Metab Dis; 2010 Jun; 33(3):281-9. PubMed ID: 20336375
[TBL] [Abstract][Full Text] [Related]
6. Bone manifestations in neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy.
Potnis KC; Flueckinger LB; Ha CI; Upadia J; Frush DP; Kishnani PS
Mol Genet Metab; 2019 Feb; 126(2):157-161. PubMed ID: 30448006
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
Ceravolo F; Grisolia M; Sestito S; Falvo F; Moricca MT; Concolino D
J Med Case Rep; 2017 Jan; 11(1):19. PubMed ID: 28103924
[TBL] [Abstract][Full Text] [Related]
8. Generation of osteoclasts from type 1 Gaucher patients and correlation with clinical and genetic features of disease.
Reed MC; Bauernfreund Y; Cunningham N; Beaton B; Mehta AB; Hughes DA
Gene; 2018 Dec; 678():196-206. PubMed ID: 30099023
[TBL] [Abstract][Full Text] [Related]
9. Proinflammatory and proosteoclastogenic potential of peripheral blood mononuclear cells from Gaucher patients: Implication for bone pathology.
Mucci JM; Cuello MF; Kisinovsky I; Larroude M; Delpino MV; Rozenfeld PA
Blood Cells Mol Dis; 2015 Aug; 55(2):134-43. PubMed ID: 26142329
[TBL] [Abstract][Full Text] [Related]
10. Gaucher disease and bone: laboratory and skeletal mineral density variations during a long period of enzyme replacement therapy.
Ciana G; Addobbati R; Tamaro G; Leopaldi A; Nevyjel M; Ronfani L; Vidoni L; Pittis MG; Bembi B
J Inherit Metab Dis; 2005; 28(5):723-32. PubMed ID: 16151904
[TBL] [Abstract][Full Text] [Related]
11. Use of plain radiography to optimize skeletal outcomes in children with type 1 Gaucher disease in Brazil.
Mota RM; Mankin H
J Pediatr Orthop; 2007; 27(3):347-50. PubMed ID: 17414023
[TBL] [Abstract][Full Text] [Related]
12. Impact on bone microarchitecture and failure load in a patient with type I Gaucher disease who switched from Imiglucerase to Eliglustat.
Sidhu K; Boyd SK; Khan A
Mol Genet Metab Rep; 2020 Sep; 24():100606. PubMed ID: 32509532
[TBL] [Abstract][Full Text] [Related]
13. Impact of imiglucerase on the serum glycosylated-ferritin level in Gaucher disease.
Stirnemann J; Boutten A; Vincent C; Mekinian A; Heraoui D; Fantin B; Fain O; Mentré F; Belmatoug N
Blood Cells Mol Dis; 2011 Jan; 46(1):34-8. PubMed ID: 21084203
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of B regulatory cells and upregulation of T helper 1 cells in children with Gaucher disease undergoing enzyme replacement therapy.
Zahran AM; Youssef MAM; Shafik EA; Zahran ZAM; El-Badawy O; Abo Elgheet AM; Elsayh KI
Immunol Res; 2020 Apr; 68(2):73-80. PubMed ID: 32524332
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Evaluation of Biomarkers in the Czech Cohort of Gaucher Patients.
Malinová V; Poupětová H; Řeboun M; Dvořáková L; Reichmannová S; Švandová I; Murgašová L; Kasper DC; Magner M
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833892
[TBL] [Abstract][Full Text] [Related]
16. Glucosylsphingosine is a key biomarker of Gaucher disease.
Murugesan V; Chuang WL; Liu J; Lischuk A; Kacena K; Lin H; Pastores GM; Yang R; Keutzer J; Zhang K; Mistry PK
Am J Hematol; 2016 Nov; 91(11):1082-1089. PubMed ID: 27441734
[TBL] [Abstract][Full Text] [Related]
17. Gaucher disease: unmet treatment needs.
Mehta A
Acta Paediatr; 2008 Apr; 97(457):83-7. PubMed ID: 18339195
[TBL] [Abstract][Full Text] [Related]
18. Gaucher disease and its treatment options.
Bennett LL; Mohan D
Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
[TBL] [Abstract][Full Text] [Related]
19. Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment.
Piran S; Amato D
J Inherit Metab Dis; 2010 Jun; 33(3):271-9. PubMed ID: 20336376
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous regression of disease manifestations can occur in type 1 Gaucher disease; results of a retrospective cohort study.
Boomsma JM; van Dussen L; Wiersma MG; Groener JE; Aerts JM; Maas M; Hollak CE
Blood Cells Mol Dis; 2010 Mar; 44(3):181-7. PubMed ID: 20074983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
